Details for Patent: 8,193,204

« Back to Dashboard

Which drugs does patent 8,193,204 protect, and when does it expire?

Patent 8,193,204 protects XERMELO and is included in one NDA.

This patent has twenty-nine patent family members in twenty-five countries.

Summary for Patent: 8,193,204

Title:	Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use
Abstract:	Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate and salts thereof are disclosed.
Inventor(s):	Mark S. Bednarz, Susan de Paul, Ramanaiah C. Kanamarlapudi, Anett Perlberg, HaiMing Zhang
Assignee:	Tersera Therapeutics LLC
Application Number:	US12/237,455
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,193,204

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tersera	XERMELO	telotristat etiprate	TABLET;ORAL	208794-001	Feb 28, 2017		RX	Yes	Yes				Y

International Family Members for US Patent 8,193,204

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	068558
Australia	2008304439
Brazil	PI0817270
Canada	2700835
Chile	2008002880
China	101809018
Colombia	6270325